Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Liabilities and Shareholders Equity: 2022-2025

Historic Liabilities and Shareholders Equity for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $360.3 million.

  • Stoke Therapeutics' Liabilities and Shareholders Equity rose 22.82% to $360.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 37.56%. This contributed to the annual value of $271.6 million for FY2024, which is 18.92% up from last year.
  • As of Q3 2025, Stoke Therapeutics' Liabilities and Shareholders Equity stood at $360.3 million, which was down 6.31% from $384.5 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Liabilities and Shareholders Equity registered a high of $406.9 million during Q1 2025, and its lowest value of $205.2 million during Q1 2024.
  • Over the past 3 years, Stoke Therapeutics' median Liabilities and Shareholders Equity value was $281.8 million (recorded in 2023), while the average stood at $294.2 million.
  • Per our database at Business Quant, Stoke Therapeutics' Liabilities and Shareholders Equity declined by 27.19% in 2024 and then surged by 98.31% in 2025.
  • Stoke Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $256.1 million in 2022, then fell by 10.83% to $228.3 million in 2023, then increased by 18.92% to $271.6 million in 2024, then climbed by 22.82% to $360.3 million in 2025.
  • Its Liabilities and Shareholders Equity was $360.3 million in Q3 2025, compared to $384.5 million in Q2 2025 and $406.9 million in Q1 2025.